View in EDS

Clioquinol inhibits angiogenesis by promoting VEGFR2 degradation and synergizes with AKT inhibition to suppress triple-negative breast cancer vascularization.

Saved in:

Bibliographic Details
Title:	Clioquinol inhibits angiogenesis by promoting VEGFR2 degradation and synergizes with AKT inhibition to suppress triple-negative breast cancer vascularization.
Authors:	Gu Y; Institute for Clinical and Experimental Surgery, Saarland University, 66421, Homburg, Saarland, Germany. yuan.gu@uks.eu., Tang T; Institute for Clinical and Experimental Surgery, Saarland University, 66421, Homburg, Saarland, Germany., Qiu M; Institute for Clinical and Experimental Surgery, Saarland University, 66421, Homburg, Saarland, Germany.; Department of Respiratory Oncology, Guangxi Medical University Cancer Hospital, Nanning, 530021, China., Wang H; Shaanxi University of Chinese Medicine, Shaanxi, 712046, China., Ampofo E; Institute for Clinical and Experimental Surgery, Saarland University, 66421, Homburg, Saarland, Germany., Menger MD; Institute for Clinical and Experimental Surgery, Saarland University, 66421, Homburg, Saarland, Germany., Laschke MW; Institute for Clinical and Experimental Surgery, Saarland University, 66421, Homburg, Saarland, Germany.
Source:	Angiogenesis [Angiogenesis] 2025 Feb 03; Vol. 28 (2), pp. 13. Date of Electronic Publication: 2025 Feb 03.
Publication Type:	Journal Article; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: Springer Country of Publication: Germany NLM ID: 9814575 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-7209 (Electronic) Linking ISSN: 09696970 NLM ISO Abbreviation: Angiogenesis Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1573-7209
DOI:	10.1007/s10456-024-09965-1